Cogniscreen
Boston, MA, US
Cogniscreen operates as Cognimark, a neurology AI platform for dementia detection and differential diagnosis. It leverages proprietary machine learning models developed through multi-million dollar funded research at Boston University and MIT.
Source: HealthTechAlpha
HealthTechAlpha provided this information. To learn more and get deep data on all digital health companies, please visit them here.
Visit HealthTechAlpha →Problem Statement
Cogniscreen addresses the challenge of accurately diagnosing dementia etiologies and stratifying risk in cognitively impaired individuals, aiming to improve patient outcomes and physician efficiency.
Core Technology
Cogniscreen's core technology is a proprietary multimodal deep learning model, developed over years of research, for AI-based differential diagnosis and risk stratification of cognitively impaired individuals.
Key Differentiators
Published research in Nature Medicine (2024); Published research in iScience (2023); Published research in Nature Communications (2022); Published research in Brain (2020); Integrated with EHR platforms Athena and eClinicalWorks; Live deployments across multiple healthcare sites; Dataset growing beyond 100,000 patients; Focus on clinical trial recruitment optimization
Clinical Focus
Neurology; Cognitive Impairment
Company Info
- Business Model
- B2B SaaS
- Website
- www.cognimark.ai/
Categories
Disease Areas
Technologies
MedStartr Index Score
?What do you think of Cogniscreen?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.